Radioactive Monoclonal Antibody Market Report

Japan Radioactive Monoclonal Antibody Market Professional Research Report 2014-2026, Segmented by Players, Types, End-Users in Major Region

  • POSTDATE：Sep 14, 2019
  • PAGES：200
  • REPORT CODE：GMM224750
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report offers an overview of the market trends, drivers, and barriers with respect to the Japan Radioactive Monoclonal Antibody market. It also provides a detailed overview of the market of different regions across Hokkaido, Tohoku, Kanto, Chubu, Kinki, Chugoku, Shikoku, Kyushu. The report deep analyzes type and application in Japan Radioactive Monoclonal Antibody market. Detailed analysis of key players, along with key growth strategies adopted by Radioactive Monoclonal Antibody industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.


    By Player:

    • Amgen Inc (USA)

    • EUSA Pharma, (USA) Inc (USA)

    • Bristol-Myers Squibb Company (USA)

    • Pfizer Inc. (USA)

    • Indevus Pharmaceuticals Inc (USA)

    • F. Hoffmann-La Roche Ltd. (Switzerland)

    • OSI Pharmaceuticals, Inc (USA)

    • Novartis AG (Switzerland)

    • Spectrum Pharmaceuticals, Inc. (USA)

    • Dendreon Corporation (USA)

    • Indevus Pharmaceuticals Inc. (USA)

    • AstraZeneca PLC (UK)

    • OSI Pharmaceuticals, Inc. (USA)

    • Immunomedics, Inc. (USA)

    • Progenics Pharmaceuticals, Inc. (USA)

    • Amgen Inc. (USA)

    • Paladin Labs Inc. (Canada)

    • Cell Genesys Inc. (USA)

    • Genentech Inc. (USA)

    • Genentech Inc (USA)

    • Sanofi-Aventis SA (France)

    • EUSA Pharma, (USA) Inc. (USA)


    By Type:

    • Type 1

    • Type 2

    • Type 3


    By End-User:

    • End-Users 1

    • End-Users 2

    • End-Users 3


    By Region:

    • Hokkaido

    • Tohoku

    • Kanto

    • Chubu

    • Kinki

    • Chugoku

    • Shikoku

    • Kyushu

  • 1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Radioactive Monoclonal Antibody Market

    • 1.3 Market Segment by Type

      • 1.3.1 Japan Radioactive Monoclonal Antibody Market Size and Growth Rate of Type 1 from 2014 to 2026

      • 1.3.2 Japan Radioactive Monoclonal Antibody Market Size and Growth Rate of Type 2 from 2014 to 2026

      • 1.3.3 Japan Radioactive Monoclonal Antibody Market Size and Growth Rate of Type 3 from 2014 to 2026

    • 1.4 Market Segment by Application

      • 1.4.1 Japan Radioactive Monoclonal Antibody Market Size and Growth Rate of Application 1 from 2014 to 2026

      • 1.4.2 Japan Radioactive Monoclonal Antibody Market Size and Growth Rate of Application 2 from 2014 to 2026

      • 1.4.3 Japan Radioactive Monoclonal Antibody Market Size and Growth Rate of Application 3 from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Hokkaido Radioactive Monoclonal Antibody Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 Tohoku Radioactive Monoclonal Antibody Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 Kanto Radioactive Monoclonal Antibody Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Chubu Radioactive Monoclonal Antibody Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Kinki Radioactive Monoclonal Antibody Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Chugoku Radioactive Monoclonal Antibody Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Shikoku Radioactive Monoclonal Antibody Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Kyushu Radioactive Monoclonal Antibody Consumption Market Size and Growth Rate from 2014 to 2026


    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants


    3 Segmentation of Radioactive Monoclonal Antibody Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Vendors

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Radioactive Monoclonal Antibody by Major Types

      • 3.4.1 Market Size and Growth Rate of Type 1

      • 3.4.2 Market Size and Growth Rate of Type 2

      • 3.4.3 Market Size and Growth Rate of Type 3

    4 Segmentation of Radioactive Monoclonal Antibody Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Radioactive Monoclonal Antibody by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Radioactive Monoclonal Antibody in Application 1

      • 4.4.2 Market Size and Growth Rate of Radioactive Monoclonal Antibody in Application 2

      • 4.4.3 Market Size and Growth Rate of Radioactive Monoclonal Antibody in Application 3


    5 Market Analysis by Regions

    • 5.1 Japan Radioactive Monoclonal Antibody Production Analysis by Regions

    • 5.2 Japan Radioactive Monoclonal Antibody Consumption Analysis by Regions


    6 Hokkaido Radioactive Monoclonal Antibody Landscape Analysis

    • 6.1 Hokkaido Radioactive Monoclonal Antibody Landscape Analysis by Major Types

    • 6.2 Hokkaido Radioactive Monoclonal Antibody Landscape Analysis by Major End-Users


    7 Tohoku Radioactive Monoclonal Antibody Landscape Analysis

    • 7.1 Tohoku Radioactive Monoclonal Antibody Landscape Analysis by Major Types

    • 7.2 Tohoku Radioactive Monoclonal Antibody Landscape Analysis by Major End-Users


    8 Kanto Radioactive Monoclonal Antibody Landscape Analysis

    • 8.1 Kanto Radioactive Monoclonal Antibody Landscape Analysis by Major Types

    • 8.2 Kanto Radioactive Monoclonal Antibody Landscape Analysis by Major End-Users


    9 Chubu Radioactive Monoclonal Antibody Landscape Analysis

    • 9.1 Chubu Radioactive Monoclonal Antibody Landscape Analysis by Major Types

    • 9.2 Chubu Radioactive Monoclonal Antibody Landscape Analysis by Major End-Users


    10 Kinki Radioactive Monoclonal Antibody Landscape Analysis

    • 10.1 Kinki Radioactive Monoclonal Antibody Landscape Analysis by Major Types

    • 10.2 Kinki Radioactive Monoclonal Antibody Landscape Analysis by Major End-Users


    11 Chugoku Radioactive Monoclonal Antibody Landscape Analysis

    • 11.1 Chugoku Radioactive Monoclonal Antibody Landscape Analysis by Major Types

    • 11.2 Chugoku Radioactive Monoclonal Antibody Landscape Analysis by Major End-Users


    12 Shikoku Radioactive Monoclonal Antibody Landscape Analysis

    • 12.1 Shikoku Radioactive Monoclonal Antibody Landscape Analysis by Major Types

    • 12.2 Shikoku Radioactive Monoclonal Antibody Landscape Analysis by Major End-Users


    13 Kyushu Radioactive Monoclonal Antibody Landscape Analysis

    • 13.1 Kyushu Radioactive Monoclonal Antibody Landscape Analysis by Major Types

    • 13.2 Kyushu Radioactive Monoclonal Antibody Landscape Analysis by Major End-Users


    14 Major Players Profiles

    • 14.1 Amgen Inc (USA)

      • 14.1.1 Amgen Inc (USA) Company Profile and Recent Development

      • 14.1.2 Market Performance

      • 14.1.3 Product and Service Introduction

    • 14.2 EUSA Pharma, (USA) Inc (USA)

      • 14.2.1 EUSA Pharma, (USA) Inc (USA) Company Profile and Recent Development

      • 14.2.2 Market Performance

      • 14.2.3 Product and Service Introduction

    • 14.3 Bristol-Myers Squibb Company (USA)

      • 14.3.1 Bristol-Myers Squibb Company (USA) Company Profile and Recent Development

      • 14.3.2 Market Performance

      • 14.3.3 Product and Service Introduction

    • 14.4 Pfizer Inc. (USA)

      • 14.4.1 Pfizer Inc. (USA) Company Profile and Recent Development

      • 14.4.2 Market Performance

      • 14.4.3 Product and Service Introduction

    • 14.5 Indevus Pharmaceuticals Inc (USA)

      • 14.5.1 Indevus Pharmaceuticals Inc (USA) Company Profile and Recent Development

      • 14.5.2 Market Performance

      • 14.5.3 Product and Service Introduction

    • 14.6 F. Hoffmann-La Roche Ltd. (Switzerland)

      • 14.6.1 F. Hoffmann-La Roche Ltd. (Switzerland) Company Profile and Recent Development

      • 14.6.2 Market Performance

      • 14.6.3 Product and Service Introduction

    • 14.7 OSI Pharmaceuticals, Inc (USA)

      • 14.7.1 OSI Pharmaceuticals, Inc (USA) Company Profile and Recent Development

      • 14.7.2 Market Performance

      • 14.7.3 Product and Service Introduction

    • 14.8 Novartis AG (Switzerland)

      • 14.8.1 Novartis AG (Switzerland) Company Profile and Recent Development

      • 14.8.2 Market Performance

      • 14.8.3 Product and Service Introduction

    • 14.9 Spectrum Pharmaceuticals, Inc. (USA)

      • 14.9.1 Spectrum Pharmaceuticals, Inc. (USA) Company Profile and Recent Development

      • 14.9.2 Market Performance

      • 14.9.3 Product and Service Introduction

    • 14.10 Dendreon Corporation (USA)

      • 14.10.1 Dendreon Corporation (USA) Company Profile and Recent Development

      • 14.10.2 Market Performance

      • 14.10.3 Product and Service Introduction

    • 14.11 Indevus Pharmaceuticals Inc. (USA)

      • 14.11.1 Indevus Pharmaceuticals Inc. (USA) Company Profile and Recent Development

      • 14.11.2 Market Performance

      • 14.11.3 Product and Service Introduction

    • 14.12 AstraZeneca PLC (UK)

      • 14.12.1 AstraZeneca PLC (UK) Company Profile and Recent Development

      • 14.12.2 Market Performance

      • 14.12.3 Product and Service Introduction

    • 14.13 OSI Pharmaceuticals, Inc. (USA)

      • 14.13.1 OSI Pharmaceuticals, Inc. (USA) Company Profile and Recent Development

      • 14.13.2 Market Performance

      • 14.13.3 Product and Service Introduction

    • 14.14 Immunomedics, Inc. (USA)

      • 14.14.1 Immunomedics, Inc. (USA) Company Profile and Recent Development

      • 14.14.2 Market Performance

      • 14.14.3 Product and Service Introduction

    • 14.15 Progenics Pharmaceuticals, Inc. (USA)

      • 14.15.1 Progenics Pharmaceuticals, Inc. (USA) Company Profile and Recent Development

      • 14.15.2 Market Performance

      • 14.15.3 Product and Service Introduction

    • 14.16 Amgen Inc. (USA)

      • 14.16.1 Amgen Inc. (USA) Company Profile and Recent Development

      • 14.16.2 Market Performance

      • 14.16.3 Product and Service Introduction

    • 14.17 Paladin Labs Inc. (Canada)

      • 14.17.1 Paladin Labs Inc. (Canada) Company Profile and Recent Development

      • 14.17.2 Market Performance

      • 14.17.3 Product and Service Introduction

    • 14.18 Cell Genesys Inc. (USA)

      • 14.18.1 Cell Genesys Inc. (USA) Company Profile and Recent Development

      • 14.18.2 Market Performance

      • 14.18.3 Product and Service Introduction

    • 14.19 Genentech Inc. (USA)

      • 14.19.1 Genentech Inc. (USA) Company Profile and Recent Development

      • 14.19.2 Market Performance

      • 14.19.3 Product and Service Introduction

    • 14.20 Genentech Inc (USA)

      • 14.20.1 Genentech Inc (USA) Company Profile and Recent Development

      • 14.20.2 Market Performance

      • 14.20.3 Product and Service Introduction

    • 14.21 Sanofi-Aventis SA (France)

      • 14.21.1 Sanofi-Aventis SA (France) Company Profile and Recent Development

      • 14.21.2 Market Performance

      • 14.21.3 Product and Service Introduction

    • 14.22 EUSA Pharma, (USA) Inc. (USA)

      • 14.22.1 EUSA Pharma, (USA) Inc. (USA) Company Profile and Recent Development

      • 14.22.2 Market Performance

      • 14.22.3 Product and Service Introduction

     

    The List of Tables and Figures (Totals 83 Figures and 128 Tables)

     

    • Figure Japan Radioactive Monoclonal Antibody Market Size and Growth Rate of Type 1 from 2014 to 2026

    • Figure Japan Radioactive Monoclonal Antibody Market Size and Growth Rate of Type 2 from 2014 to 2026

    • Figure Japan Radioactive Monoclonal Antibody Market Size and Growth Rate of Type 3 from 2014 to 2026

    • Figure Market Share by Type in 2014

    • Figure Market Share by Type in 2018

    • Figure Market Share by Type in 2026

    • Figure Japan Radioactive Monoclonal Antibody Market Size and Growth Rate of Application 1 from 2014 to 2026

    • Figure Japan Radioactive Monoclonal Antibody Market Size and Growth Rate of Application 2 from 2014 to 2026

    • Figure Japan Radioactive Monoclonal Antibody Market Size and Growth Rate of Application 3 from 2014 to 2026

    • Figure Market Share by End-User in 2014

    • Figure Market Share by End-User in 2018

    • Figure Market Share by End-User in 2026

    • Figure Hokkaido Radioactive Monoclonal Antibody Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Tohoku Radioactive Monoclonal Antibody Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kanto Radioactive Monoclonal Antibody Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Chubu Radioactive Monoclonal Antibody Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kinki Radioactive Monoclonal Antibody Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Chugoku Radioactive Monoclonal Antibody Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Shikoku Radioactive Monoclonal Antibody Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kyushu Radioactive Monoclonal Antibody Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Radioactive Monoclonal Antibody Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 3 Players in 2018

    • Figure Market Share of TOP 5 Players in 2018

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Radioactive Monoclonal Antibody

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Radioactive Monoclonal Antibody by Different Types from 2014 to 2026

    • Table Consumption Share of Radioactive Monoclonal Antibody by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of Type 1

    • Figure Market Size and Growth Rate of Type 2

    • Figure Market Size and Growth Rate of Type 3

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Radioactive Monoclonal Antibody by Different End-Users from 2014 to 2026

    • Table Consumption Share of Radioactive Monoclonal Antibody by Different End-Users from 2014 to 2026

    • Figure Japan Radioactive Monoclonal Antibody Market Size and Growth Rate of Application 1 from 2014 to 2026

    • Figure Japan Radioactive Monoclonal Antibody Market Size and Growth Rate of Application 2 from 2014 to 2026

    • Figure Japan Radioactive Monoclonal Antibody Market Size and Growth Rate of Application 3 from 2014 to 2026

    • Table Japan Radioactive Monoclonal Antibody Production by Regions

    • Table Japan Radioactive Monoclonal Antibody Production Share by Regions

    • Figure Japan Radioactive Monoclonal Antibody Production Share by Regions in 2014

    • Figure Japan Radioactive Monoclonal Antibody Production Share by Regions in 2018

    • Figure Japan Radioactive Monoclonal Antibody Production Share by Regions in 2026

    • Table Japan Radioactive Monoclonal Antibody Consumption by Regions

    • Table Japan Radioactive Monoclonal Antibody Consumption Share by Regions

    • Figure Japan Radioactive Monoclonal Antibody Consumption Share by Regions in 2014

    • Figure Japan Radioactive Monoclonal Antibody Consumption Share by Regions in 2018

    • Figure Japan Radioactive Monoclonal Antibody Consumption Share by Regions in 2026

    • Table Hokkaido Radioactive Monoclonal Antibody Consumption by Types from 2014 to 2026

    • Table Hokkaido Radioactive Monoclonal Antibody Consumption Share by Types from 2014 to 2026

    • Figure Hokkaido Radioactive Monoclonal Antibody Consumption Share by Types in 2014

    • Figure Hokkaido Radioactive Monoclonal Antibody Consumption Share by Types in 2018

    • Figure Hokkaido Radioactive Monoclonal Antibody Consumption Share by Types in 2026

    • Table Hokkaido Radioactive Monoclonal Antibody Consumption by End-Users from 2014 to 2026

    • Table Hokkaido Radioactive Monoclonal Antibody Consumption Share by End-Users from 2014 to 2026

    • Figure Hokkaido Radioactive Monoclonal Antibody Consumption Share by End-Users in 2014

    • Figure Hokkaido Radioactive Monoclonal Antibody Consumption Share by End-Users in 2018

    • Figure Hokkaido Radioactive Monoclonal Antibody Consumption Share by End-Users in 2026

    • Table Tohoku Radioactive Monoclonal Antibody Consumption by Types from 2014 to 2026

    • Table Tohoku Radioactive Monoclonal Antibody Consumption Share by Types from 2014 to 2026

    • Figure Tohoku Radioactive Monoclonal Antibody Consumption Share by Types in 2014

    • Figure Tohoku Radioactive Monoclonal Antibody Consumption Share by Types in 2018

    • Figure Tohoku Radioactive Monoclonal Antibody Consumption Share by Types in 2026

    • Table Tohoku Radioactive Monoclonal Antibody Consumption by End-Users from 2014 to 2026

    • Table Tohoku Radioactive Monoclonal Antibody Consumption Share by End-Users from 2014 to 2026

    • Figure Tohoku Radioactive Monoclonal Antibody Consumption Share by End-Users in 2014

    • Figure Tohoku Radioactive Monoclonal Antibody Consumption Share by End-Users in 2018

    • Figure Tohoku Radioactive Monoclonal Antibody Consumption Share by End-Users in 2026

    • Table Kanto Radioactive Monoclonal Antibody Consumption by Types from 2014 to 2026

    • Table Kanto Radioactive Monoclonal Antibody Consumption Share by Types from 2014 to 2026

    • Figure Kanto Radioactive Monoclonal Antibody Consumption Share by Types in 2014

    • Figure Kanto Radioactive Monoclonal Antibody Consumption Share by Types in 2018

    • Figure Kanto Radioactive Monoclonal Antibody Consumption Share by Types in 2026

    • Table Kanto Radioactive Monoclonal Antibody Consumption by End-Users from 2014 to 2026

    • Table Kanto Radioactive Monoclonal Antibody Consumption Share by End-Users from 2014 to 2026

    • Figure Kanto Radioactive Monoclonal Antibody Consumption Share by End-Users in 2014

    • Figure Kanto Radioactive Monoclonal Antibody Consumption Share by End-Users in 2018

    • Figure Kanto Radioactive Monoclonal Antibody Consumption Share by End-Users in 2026

    • Table Chubu Radioactive Monoclonal Antibody Consumption by Types from 2014 to 2026

    • Table Chubu Radioactive Monoclonal Antibody Consumption Share by Types from 2014 to 2026

    • Figure Chubu Radioactive Monoclonal Antibody Consumption Share by Types in 2014

    • Figure Chubu Radioactive Monoclonal Antibody Consumption Share by Types in 2018

    • Figure Chubu Radioactive Monoclonal Antibody Consumption Share by Types in 2026

    • Table Chubu Radioactive Monoclonal Antibody Consumption by End-Users from 2014 to 2026

    • Table Chubu Radioactive Monoclonal Antibody Consumption Share by End-Users from 2014 to 2026

    • Figure Chubu Radioactive Monoclonal Antibody Consumption Share by End-Users in 2014

    • Figure Chubu Radioactive Monoclonal Antibody Consumption Share by End-Users in 2018

    • Figure Chubu Radioactive Monoclonal Antibody Consumption Share by End-Users in 2026

    • Table Kinki Radioactive Monoclonal Antibody Consumption by Types from 2014 to 2026

    • Table Kinki Radioactive Monoclonal Antibody Consumption Share by Types from 2014 to 2026

    • Figure Kinki Radioactive Monoclonal Antibody Consumption Share by Types in 2014

    • Figure Kinki Radioactive Monoclonal Antibody Consumption Share by Types in 2018

    • Figure Kinki Radioactive Monoclonal Antibody Consumption Share by Types in 2026

    • Table Kinki Radioactive Monoclonal Antibody Consumption by End-Users from 2014 to 2026

    • Table Kinki Radioactive Monoclonal Antibody Consumption Share by End-Users from 2014 to 2026

    • Figure Kinki Radioactive Monoclonal Antibody Consumption Share by End-Users in 2014

    • Figure Kinki Radioactive Monoclonal Antibody Consumption Share by End-Users in 2018

    • Figure Kinki Radioactive Monoclonal Antibody Consumption Share by End-Users in 2026

    • Table Chugoku Radioactive Monoclonal Antibody Consumption by Types from 2014 to 2026

    • Table Chugoku Radioactive Monoclonal Antibody Consumption Share by Types from 2014 to 2026

    • Figure Chugoku Radioactive Monoclonal Antibody Consumption Share by Types in 2014

    • Figure Chugoku Radioactive Monoclonal Antibody Consumption Share by Types in 2018

    • Figure Chugoku Radioactive Monoclonal Antibody Consumption Share by Types in 2026

    • Table Chugoku Radioactive Monoclonal Antibody Consumption by End-Users from 2014 to 2026

    • Table Chugoku Radioactive Monoclonal Antibody Consumption Share by End-Users from 2014 to 2026

    • Figure Chugoku Radioactive Monoclonal Antibody Consumption Share by End-Users in 2014

    • Figure Chugoku Radioactive Monoclonal Antibody Consumption Share by End-Users in 2018

    • Figure Chugoku Radioactive Monoclonal Antibody Consumption Share by End-Users in 2026

    • Table Shikoku Radioactive Monoclonal Antibody Consumption by Types from 2014 to 2026

    • Table Shikoku Radioactive Monoclonal Antibody Consumption Share by Types from 2014 to 2026

    • Figure Shikoku Radioactive Monoclonal Antibody Consumption Share by Types in 2014

    • Figure Shikoku Radioactive Monoclonal Antibody Consumption Share by Types in 2018

    • Figure Shikoku Radioactive Monoclonal Antibody Consumption Share by Types in 2026

    • Table Shikoku Radioactive Monoclonal Antibody Consumption by End-Users from 2014 to 2026

    • Table Shikoku Radioactive Monoclonal Antibody Consumption Share by End-Users from 2014 to 2026

    • Figure Shikoku Radioactive Monoclonal Antibody Consumption Share by End-Users in 2014

    • Figure Shikoku Radioactive Monoclonal Antibody Consumption Share by End-Users in 2018

    • Figure Shikoku Radioactive Monoclonal Antibody Consumption Share by End-Users in 2026

    • Table Kyushu Radioactive Monoclonal Antibody Consumption by Types from 2014 to 2026

    • Table Kyushu Radioactive Monoclonal Antibody Consumption Share by Types from 2014 to 2026

    • Figure Kyushu Radioactive Monoclonal Antibody Consumption Share by Types in 2014

    • Figure Kyushu Radioactive Monoclonal Antibody Consumption Share by Types in 2018

    • Figure Kyushu Radioactive Monoclonal Antibody Consumption Share by Types in 2026

    • Table Kyushu Radioactive Monoclonal Antibody Consumption by End-Users from 2014 to 2026

    • Table Kyushu Radioactive Monoclonal Antibody Consumption Share by End-Users from 2014 to 2026

    • Figure Kyushu Radioactive Monoclonal Antibody Consumption Share by End-Users in 2014

    • Figure Kyushu Radioactive Monoclonal Antibody Consumption Share by End-Users in 2018

    • Figure Kyushu Radioactive Monoclonal Antibody Consumption Share by End-Users in 2026

    • Table Company Profile and Development Status of Amgen Inc (USA)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Amgen Inc (USA)

    • Figure Sales and Growth Rate Analysis of Amgen Inc (USA)

    • Figure Revenue and Market Share Analysis of Amgen Inc (USA)

    • Table Product and Service Introduction of Amgen Inc (USA)

    • Table Company Profile and Development Status of EUSA Pharma, (USA) Inc (USA)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of EUSA Pharma, (USA) Inc (USA)

    • Figure Sales and Growth Rate Analysis of EUSA Pharma, (USA) Inc (USA)

    • Figure Revenue and Market Share Analysis of EUSA Pharma, (USA) Inc (USA)

    • Table Product and Service Introduction of EUSA Pharma, (USA) Inc (USA)

    • Table Company Profile and Development Status of Bristol-Myers Squibb Company (USA)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bristol-Myers Squibb Company (USA)

    • Figure Sales and Growth Rate Analysis of Bristol-Myers Squibb Company (USA)

    • Figure Revenue and Market Share Analysis of Bristol-Myers Squibb Company (USA)

    • Table Product and Service Introduction of Bristol-Myers Squibb Company (USA)

    • Table Company Profile and Development Status of Pfizer Inc. (USA)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer Inc. (USA)

    • Figure Sales and Growth Rate Analysis of Pfizer Inc. (USA)

    • Figure Revenue and Market Share Analysis of Pfizer Inc. (USA)

    • Table Product and Service Introduction of Pfizer Inc. (USA)

    • Table Company Profile and Development Status of Indevus Pharmaceuticals Inc (USA)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Indevus Pharmaceuticals Inc (USA)

    • Figure Sales and Growth Rate Analysis of Indevus Pharmaceuticals Inc (USA)

    • Figure Revenue and Market Share Analysis of Indevus Pharmaceuticals Inc (USA)

    • Table Product and Service Introduction of Indevus Pharmaceuticals Inc (USA)

    • Table Company Profile and Development Status of F. Hoffmann-La Roche Ltd. (Switzerland)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of F. Hoffmann-La Roche Ltd. (Switzerland)

    • Figure Sales and Growth Rate Analysis of F. Hoffmann-La Roche Ltd. (Switzerland)

    • Figure Revenue and Market Share Analysis of F. Hoffmann-La Roche Ltd. (Switzerland)

    • Table Product and Service Introduction of F. Hoffmann-La Roche Ltd. (Switzerland)

    • Table Company Profile and Development Status of OSI Pharmaceuticals, Inc (USA)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of OSI Pharmaceuticals, Inc (USA)

    • Figure Sales and Growth Rate Analysis of OSI Pharmaceuticals, Inc (USA)

    • Figure Revenue and Market Share Analysis of OSI Pharmaceuticals, Inc (USA)

    • Table Product and Service Introduction of OSI Pharmaceuticals, Inc (USA)

    • Table Company Profile and Development Status of Novartis AG (Switzerland)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novartis AG (Switzerland)

    • Figure Sales and Growth Rate Analysis of Novartis AG (Switzerland)

    • Figure Revenue and Market Share Analysis of Novartis AG (Switzerland)

    • Table Product and Service Introduction of Novartis AG (Switzerland)

    • Table Company Profile and Development Status of Spectrum Pharmaceuticals, Inc. (USA)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Spectrum Pharmaceuticals, Inc. (USA)

    • Figure Sales and Growth Rate Analysis of Spectrum Pharmaceuticals, Inc. (USA)

    • Figure Revenue and Market Share Analysis of Spectrum Pharmaceuticals, Inc. (USA)

    • Table Product and Service Introduction of Spectrum Pharmaceuticals, Inc. (USA)

    • Table Company Profile and Development Status of Dendreon Corporation (USA)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Dendreon Corporation (USA)

    • Figure Sales and Growth Rate Analysis of Dendreon Corporation (USA)

    • Figure Revenue and Market Share Analysis of Dendreon Corporation (USA)

    • Table Product and Service Introduction of Dendreon Corporation (USA)

    • Table Company Profile and Development Status of Indevus Pharmaceuticals Inc. (USA)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Indevus Pharmaceuticals Inc. (USA)

    • Figure Sales and Growth Rate Analysis of Indevus Pharmaceuticals Inc. (USA)

    • Figure Revenue and Market Share Analysis of Indevus Pharmaceuticals Inc. (USA)

    • Table Product and Service Introduction of Indevus Pharmaceuticals Inc. (USA)

    • Table Company Profile and Development Status of AstraZeneca PLC (UK)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of AstraZeneca PLC (UK)

    • Figure Sales and Growth Rate Analysis of AstraZeneca PLC (UK)

    • Figure Revenue and Market Share Analysis of AstraZeneca PLC (UK)

    • Table Product and Service Introduction of AstraZeneca PLC (UK)

    • Table Company Profile and Development Status of OSI Pharmaceuticals, Inc. (USA)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of OSI Pharmaceuticals, Inc. (USA)

    • Figure Sales and Growth Rate Analysis of OSI Pharmaceuticals, Inc. (USA)

    • Figure Revenue and Market Share Analysis of OSI Pharmaceuticals, Inc. (USA)

    • Table Product and Service Introduction of OSI Pharmaceuticals, Inc. (USA)

    • Table Company Profile and Development Status of Immunomedics, Inc. (USA)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Immunomedics, Inc. (USA)

    • Figure Sales and Growth Rate Analysis of Immunomedics, Inc. (USA)

    • Figure Revenue and Market Share Analysis of Immunomedics, Inc. (USA)

    • Table Product and Service Introduction of Immunomedics, Inc. (USA)

    • Table Company Profile and Development Status of Progenics Pharmaceuticals, Inc. (USA)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Progenics Pharmaceuticals, Inc. (USA)

    • Figure Sales and Growth Rate Analysis of Progenics Pharmaceuticals, Inc. (USA)

    • Figure Revenue and Market Share Analysis of Progenics Pharmaceuticals, Inc. (USA)

    • Table Product and Service Introduction of Progenics Pharmaceuticals, Inc. (USA)

    • Table Company Profile and Development Status of Amgen Inc. (USA)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Amgen Inc. (USA)

    • Figure Sales and Growth Rate Analysis of Amgen Inc. (USA)

    • Figure Revenue and Market Share Analysis of Amgen Inc. (USA)

    • Table Product and Service Introduction of Amgen Inc. (USA)

    • Table Company Profile and Development Status of Paladin Labs Inc. (Canada)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Paladin Labs Inc. (Canada)

    • Figure Sales and Growth Rate Analysis of Paladin Labs Inc. (Canada)

    • Figure Revenue and Market Share Analysis of Paladin Labs Inc. (Canada)

    • Table Product and Service Introduction of Paladin Labs Inc. (Canada)

    • Table Company Profile and Development Status of Cell Genesys Inc. (USA)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Cell Genesys Inc. (USA)

    • Figure Sales and Growth Rate Analysis of Cell Genesys Inc. (USA)

    • Figure Revenue and Market Share Analysis of Cell Genesys Inc. (USA)

    • Table Product and Service Introduction of Cell Genesys Inc. (USA)

    • Table Company Profile and Development Status of Genentech Inc. (USA)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Genentech Inc. (USA)

    • Figure Sales and Growth Rate Analysis of Genentech Inc. (USA)

    • Figure Revenue and Market Share Analysis of Genentech Inc. (USA)

    • Table Product and Service Introduction of Genentech Inc. (USA)

    • Table Company Profile and Development Status of Genentech Inc (USA)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Genentech Inc (USA)

    • Figure Sales and Growth Rate Analysis of Genentech Inc (USA)

    • Figure Revenue and Market Share Analysis of Genentech Inc (USA)

    • Table Product and Service Introduction of Genentech Inc (USA)

    • Table Company Profile and Development Status of Sanofi-Aventis SA (France)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sanofi-Aventis SA (France)

    • Figure Sales and Growth Rate Analysis of Sanofi-Aventis SA (France)

    • Figure Revenue and Market Share Analysis of Sanofi-Aventis SA (France)

    • Table Product and Service Introduction of Sanofi-Aventis SA (France)

    • Table Company Profile and Development Status of EUSA Pharma, (USA) Inc. (USA)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of EUSA Pharma, (USA) Inc. (USA)

    • Figure Sales and Growth Rate Analysis of EUSA Pharma, (USA) Inc. (USA)

    • Figure Revenue and Market Share Analysis of EUSA Pharma, (USA) Inc. (USA)

    • Table Product and Service Introduction of EUSA Pharma, (USA) Inc. (USA)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US